Pharmaceutical - Antibiotics and Infectious diseases

Filter

Popular Filters

201 to 220 of 220 results

Licensing deal for Basilea in sight

13-01-2012

The completion of the pneumonia data audit and confirmation of the timeline for Switzerland-based Basilea’s…

Antibiotics and Infectious diseasesBasilea PharmaceuticaceftobiproleDermatologicalsLicensingPharmaceuticalResearchToctino

Astellas pulls out of deal with Theravance

09-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) says it has exercised its right to terminate the global…

Antibiotics and Infectious diseasesAstellas PharmaLicensingPharmaceuticalTheravanceVibativ

European Medicines Agency releases adverse reaction report

05-01-2012

European Ombudsman Nikiforos Diamandouros has welcomed the European Medicines Agency's release of adverse…

Antibiotics and Infectious diseasesEuropePharmaceuticalRegulation

Astellas and Optimer’s C. difficile drug cleared in Europe

13-12-2011

Following an earlier positive recommendation from a European Medicines Agency advisory panel (The Pharma…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirEuropeOptimer PharmaceuticalsPharmaceuticalRegulation

TaiGen gets global nemonoxacin rights

11-12-2011

Taiwan’s TaiGen Biotechnology has reached a deal with Ireland-headquartered Warner Chilcott (Nasdaq:…

Antibiotics and Infectious diseasesBiotechnologyLicensingnemonoxacinPharmaceuticalTaiGen BiotecnologyWarner Chilcott

Backing for Japanese approval of Regnite, Ranmark and Cancidas

05-12-2011

USA-based XenoPort (Nasdaq: XNPT) saw its shares rise 3% to $4.73 on Friday, when the company said it…

Antibiotics and Infectious diseasesAsia-PacificCancidasDaiichi SankyodenosumabHorizantMerck & CoOncologyPharmaceuticalRegniteRegulationXenoPort

New compound defeats drug-resistant bacteria

30-11-2011

Bacteria can use efflux pumps to rid themselves of antibiotics, becoming drug-resistant until newer antibiotics…

Antibiotics and Infectious diseasesMPEX PharmaceuticalsPharmaceuticalResearch

World antibacterials market to grow to $43.8 billion in 2016, says Visiongain

29-11-2011

World revenues for antibacterial drugs will reach $43.81 billion in 2016. Between 2010 and 2022, the…

Antibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceutical

Key hospital-infections markets set to grow to over $4 billion in 2020; report

24-11-2011

Despite market constraints that include intensified competition, generic erosion and an increasingly…

Antibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceutical

EU Commission unveils 12 concrete actions against antimicrobial resistance for the next five years

17-11-2011

With about 25,000 patients dying per year in the European Union from infections caused by drug resistant…

Antibiotics and Infectious diseasesEuropePharmaceuticalRegulationResearch

Sanofi Pasteur and CureVac collaborate on a $33.1 million project on vaccines for infectious diseases

16-11-2011

Germany’s CureVac says it has signed several agreements with Sanofi Pasteur, the vaccines division…

Antibiotics and Infectious diseasesBiotechnologyCureVacLicensingPharmaceuticalResearchSanofiSanofi PasteurVaccines

US hospital pharmacy and therapeutics committees decision-making process for antibiotics and antifungal therapies

15-11-2011

In addition to managing the hospital’s anti-infective formulary, hospital pharmacy and therapeutics…

Antibiotics and Infectious diseasesGenericsMarkets & MarketingNorth AmericaPharmaceutical

US FDA should require Black Box warning for Pfizer’s antibiotic Tygacil, says Public Citizen

31-10-2011

US advocacy group Public Citizen has sent a petition to the Food and Drug Administration calling on the…

Antibiotics and Infectious diseasesNorth AmericaPfizerPharmaceuticalRegulationTygacil

EFPIA supports a new R&D model to tackle antimicrobial resistance

27-10-2011

A vote of the European Parliament’s Health Committee on the threat posed by antimicrobial resistance,…

Antibiotics and Infectious diseasesEuropePharmaceuticalPoliticsResearch

Eli Lilly pulls sepsis drug Xigris off all markets, due to lack of efficacy

26-10-2011

US drug major Eli Lilly (NYSE: LLY) revealed yesterday that it is withdrawing its Xigris (drotrecogin…

Antibiotics and Infectious diseasesEli LillyMarkets & MarketingPharmaceuticalResearchXigris

GlaxoSmithKline warned by US FDA over cGMP violations at UK plant; positive malaria vaccine news

20-10-2011

UK pharma giant GlaxoSmithKline ILSE: GSK) has received a warning letter from the US Food and Drug Administration…

Antibiotics and Infectious diseasesGlaxoSmithKlinePharmaceuticalRegulationResearchVaccines

AstraZeneca and Forest initiate Ph III trials of CAZ-AVI

18-10-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and USA-based Forest Laboratories (NYSE: FRX) said this…

Antibiotics and Infectious diseasesAstraZenecaavibactamCeftazidimeForest LaboratoriesPharmaceuticalResearch

Inconclusive Ph III results for Pfizer’s Vfend and Eraxis combo in fungal infections

03-10-2011

There was disappointing news for global drugs behemoth Pfizer (NYSE: PFE) last Friday, when the company…

Antibiotics and Infectious diseasesEraxisPfizerPharmaceuticalResearchVfend

More news from EMA/CHMP September meeting

26-09-2011

Following its meetings last week, the European Medicines Agency’s Committee for Medicinal Products…

Anti-viralsAntibiotics and Infectious diseasesAstellas PharmaCelgeneDificidDificlirEuropeEvipleraGilead SciencesOncologyPharmaceuticalRegulationRevlimidUCBVimpat

201 to 220 of 220 results

Back to top